Immunization with a LEAPS(TM) heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1

Ken S. Rosenthal, Hanwen Mao, Walter I. Horne, Craig Wright, Daniel Zimmerman

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

A ligand epitope antigen presentation system (LEAPS(TM)) heteroconjugate vaccine containing a CTL epitope (H1) from the HSV-1 immediate early protein ICP27 (322-332) and a peptide sequence (J) from β-2-microglobulin (35-50) elicited protection from intraperitoneal viral challenge and promoted DTH responses. The H1 peptide and other H1 containing heteroconjugates did not elicit protection or DTH responses. Antibody to the H1 peptide could not be detected by ELISA following vaccination with peptide, heteroconjugate or natural infection. The LEAPS(TM) heteroconjugate appears to prime a Th1-like response which is subsequently boosted by infection. These studies show that attachment of the J peptide can make a CTL epitope into a vaccine which is immunogenic and promotes a protective Th1 type of response.

Original languageEnglish (US)
Pages (from-to)535-542
Number of pages8
JournalVaccine
Volume17
Issue number6
DOIs
StatePublished - Feb 1 1999
Externally publishedYes

Keywords

  • Herpes simplex virus
  • Heteroconjugate
  • Th1 response

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunization with a LEAPS(TM) heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1'. Together they form a unique fingerprint.

  • Cite this